Echo Therapeutics, Inc. - FORM 10-Q - EX-32.2 - CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 - August 9, 2012

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.Financial_Report.xls
EX-3.1 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Echo Therapeutics, Inc.ex3-1.htm
EX-3.2 - CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES C PREFERRED STOCK - Echo Therapeutics, Inc.ex3-2.htm
EX-32.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 - Echo Therapeutics, Inc.ex32-1.htm
EX-31.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER - Echo Therapeutics, Inc.ex31-1.htm
EX-10.2 - AMENDED AND RESTATED LICENSE AGREEMENT - Echo Therapeutics, Inc.ex10-2.htm
EX-31.2 - CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER - Echo Therapeutics, Inc.ex31-2.htm
10-Q - FORM 10-Q - Echo Therapeutics, Inc.ecte10qjune302012.htm
EX-3.3 - CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES D PREFERRED STOCK - Echo Therapeutics, Inc.ex3-3.htm
Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Echo Therapeutics, Inc. (the “Company”) for the quarter ended June 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher P. Schnittker, CPA, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Christopher P. Schnittker                                                                                
Christopher P. Schnittker, CPA
Chief Financial Officer and Treasurer
(Principal Financial Officer)

August 9, 2012

Echo Therapeutics, Inc. Reports